Bing Center WM experts discuss various topics from the 11th IWWM in Madrid.

What should you know if you or a loved one has been diagnosed with Waldenström macroglobulinemia (WM)? Dr. Shayna Sarosiek of the Dana-Farber Cancer Institute shares key advice.

This document, written by Drs. Jorge Castillo and Shayna Sarosiek, provides a reference guide to assist medical professionals in discussions with WM patients. Patients can give this booklet to their PCP, oncologist, or other health care provider in order to help familiarize them with this uncommon disease.

From the 64th ASH Annual Meeting, Jorge Castillo, MD, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, updates our Waldenström patient community on important research results presented this year, offers guidance on finding relevant clinical trials, and highlights what to look for in the coming year.

RECORDING NOW AVIALABLE! Join IWMF on ZOOM for this very important topic that affects everyone with a WM diagnosis! Dr. Jorge Castillo presents - Treatments, Trials, and Hope – for ALL Stages of Disease. Dr. Castillo is a GLOBAL SPECIALIST IN Waldenstrom's Macroglobulinemia (WM) AND Clinical Director of the Bing Center Clinic (for WM) at Dana-Farber Cancer Institute.

With so many patients choosing BTK inhibitors for their Waldenstrom Macroglobulinemia treatment, and new WM treatments in development, it is difficult to keep up with so much new information. This is your chance to get Dr. Jorge Castillo's expert info about BTK inhibitors, long term goals and monitoring; what to do, what not to do; complications; and even some success stories.

IWMF grant funding for research projects has helped to provide an understanding of the basic biology and genetics of WM. This research in turn has played a significant role in the development of treatments and treatment guidelines in current use, as well as potential new drugs still in the pipeline. The goal of our research program is to improve quality of life for WM patients and, ultimately, discover a cure.

Waldenstrom’s macroglobulinemia (WM) is a rare type of cancer that begins in the white blood cells.The abnormal white blood cells produce a protein that accumulates in the blood, impairs circulation and causes complications. It continues to be a clinical challenge for treating physicians as complete remissions and prevention of relapse are few in spite of all the therapeutic tools that are currently available.  Besides treatment aspects, correct diagnosis of WM often poses a challenge.

For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report. This year, Dana-Farber Brigham Cancer Center is ranked as the best hospital for cancer care in New England and #4 in the nation.

Join us for the Walk for Waldenstrom’s 2022, Sunday, September 18th at 10:00am (ET). This is YOUR opportunity to raise awareness and support for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). Walk for Waldenstrom’s is a 1-mile walk/run fundraising and awareness event for the IWMF and global WM community of care partners, friends, and family. There’s no registration fee or charge!